Tegaserod (Zelnorm, Zelmac)

Indications


Pharmacology

  • xxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Cardiovascular/Neurologic Adverse Effects

  • Increased Risk of Cardiovascular Events: stroke, myocardial infarction
    • Novartis withdrew tegaserod in 2007 after FDA request
    • Although the relationship between tegaserod and this cardiovascular events was not supported in a large cohort study based on a US health insurance database

Gastrointestinal Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx